Newsletter · 2026-06-26 · Ashutosh Agarwal

AbbVie Buys Apogee for 10.9 Billion Capping a 134 Billion M&A Year - The Biotech Patent Cliff & M&A - Week of June 26, 2026

Biotech patent-cliff M&A newsletter for the week of June 26, 2026. AbbVie's $10.9B all-cash Apogee takeout (accretive only from 2032) became the largest biopharma-proper deal of 2026 and capped a $134B, 33-deal, six-month spree, while MRK, PFE, BMY, JNJ, VRTX, GILD and AZN stayed near-silent on the tape.

The Biotech Patent Cliff & M&A

Week of June 26, 2026: AbbVie Buys Apogee for 10.9 Billion Capping a 134 Billion M&A Year

TL;DR

• AbbVie is buying Apogee Therapeutics for $135.11/share, ~$10.9 billion all-cash, the largest "biopharma proper" deal of 2026 and the year's second-biggest behind Sun Pharma/Organon. It's an immunology bolt-on, accretive only from 2032, and it tells you the cliff-defense playbook is now "pay up early for the next Skyrizi."
• The sector has spent ~$134 billion across 33 billion-dollar-plus deals in six months, already more than all of last year. The reopening IPO window is starting to raise takeout premiums, not lower them.
• The names this newsletter watches, MRK, PFE, BMY, JNJ, VRTX, GILD, AZN, and every SMID-cap target, were near-silent on the podcast tape this week. In a week this loud on M&A, that silence is its own tell.

What's new

1. AbbVie doubles down on immunology, again. AbbVie agreed to buy Apogee for $135.11 a share, ~$10.9 billion total equity value, all cash, with both boards on board and a Q3 2026 close targeted. On BioCentury This Week, Ep. 373, "AbbVie M&A, FDA reversals, a CAR T first" (June 23), news editor Paul Bananos framed it bluntly: this is "an 11-digit takeout, actually even a little bigger than Immunogen or Cerevel," AbbVie's biggest swing since the 2023 double. The prize is Zumiloki, a half-life-extended IL-13 antibody for atopic dermatitis dosed roughly every three months versus every two-to-four weeks for Lilly's Ebglis and Sanofi/Regeneron's Dupixent. On Squawk on the Street (June 22), David Faber pegged the atopic-dermatitis market at "$50 billion-plus," with Dupixent already "like a $20 billion drug," and flagged Apogee's Phase 2 readout, two-thirds of patients reaching significant skin clearance at 16 weeks. Why it moves numbers: it's the clearest statement yet that AbbVie intends to re-run the post-Humira Skyrizi/Rinvoq trick rather than diversify away from immunology. One catch worth holding management to, it's accretive to adjusted EPS only beginning in 2032.

2. The deal is a symptom, not the story. On The Readout Loud, Ep. 407 (June 25), STAT's Allison DeAngelis put a number on the wave: "about 33 acquisitions valued at over a billion dollars" in the past six months, ~$134 billion spent, already topping a strong 2025. Her sharper point, citing PitchBook's Ben Zurcher: the reopened IPO market is pushing premiums up, because targets now have a financing alternative to selling. On BioSpace's weekly (June 24), the team slotted Apogee behind only Sun Pharma's $11.75B for Organon (April) and ahead of GSK's $10.6B Nuvalent buy, and noted Lilly had already spent ~$21 billion by the end of April. Acquirer diversity is the new feature: Incyte, Biogen and UCB are now in the mix, not just the usual mega-caps.

3. A masterclass in why a SMID-cap becomes a bidding war. The most useful 30 minutes of the week came from an operator. On Venrock's Running Through Walls, "Building a Differentiated Obesity Biotech" (June 23), MetSera CEO Whit Bernard (insider) walked through the 2025 Pfizer-vs-Novo fight over his company. His ultra-long-acting GLP-1 hit an 18 to 19 day observed half-life, "a true monthly drug," and that single differentiation drew bidders. Pfizer won round one because it "moved just a little bit faster and more decisively" and carried less antitrust baggage; then, about a month later, Novo's CEO mailed a topping bid, something Bernard says "really just doesn't happen in biopharma." The kicker for our thesis: he was explicit the asset was solving "a revenue gap associated with a patent cliff in 2029, 2030" for Pfizer. Differentiation plus speed-to-late-stage equals a premium. Tape that to your monitor next to the SMID list.

4. The franchise scoreboard quietly flipped. Per Citeline's Scrip Five Must-Know Things (June 22), Lilly's Mounjaro took the #1 quarterly bestseller spot in Q1 2026 at $8.66 billion (more than doubling YoY), ending Keytruda's reign since Q1 2023. Full-year consensus has Mounjaro at $33.1B edging Keytruda at $30.8B. And the cliff math that defines our beat: Eliquis hit $4.14B in Q1 (+16% YoY) but lost European exclusivity this May, with the US to follow in 2028. The clock on Bristol and Pfizer's anticoagulant is now visibly running.

The pattern this week: the buyers with cliffs are paying up, and the only thing scarcer than a differentiated asset is the patience to build one in-house.

The debate

The supercycle bull. A $134B, six-month deal spree is not froth, it's arithmetic. Big pharma faces a 2026 to 2030 wall (Keytruda, Eliquis, Stelara, Opdivo, and more), balance sheets are flush, and GLP-1 cash is firehosing into Lilly's BD budget. With the IPO window open and the FDA visibly reversing the restrictive Makary/Prasad-era decisions, UniQure's Huntington's program and Regenxbio's gene therapies both got reprieves this week, per BioCentury and The Readout Loud, the cost of clinical risk just fell. Premiums go up from here, and the SMID targets with genuine differentiation get bought.

The cliff-erosion bear. Look at what AbbVie actually signed: a deal that doesn't earn its keep until 2032, in a market (Dupixent's) where the incumbent has a half-decade head start. The bull case is a treadmill, even AbbVie, the poster child for surviving a cliff, "still has to keep working," as BioSpace put it. Pay 2032 money for 2026 cliffs enough times and you're funding revenue replacement at negative NPV. And the tape isn't confirming a biotech bull: on Best Stocks Now (June 25), Bill Gunderson flagged biotech as "probably the strongest sector in the market yesterday," then immediately cautioned "one or two days does not a new trend make" and said he expects memory chips, not biotech, to lead the second half.

My take. This is a buyers' arms race with a financing-cost tailwind, and it's real, but it's bifurcating. Differentiated, late-ish-stage assets (the MetSera template) will keep fetching war-premium prices; me-too pipelines will get stranded as the IPO window gives them a place to hide. The trade isn't "own the XBI." It's own the differentiation, and respect that an accretion date of 2032 is the market telling you these are defensive purchases, not growth ones.

Stocks in play

Read-throughs

• Takeout targets: the MetSera lesson is the actionable one, bidders chase format/half-life/dosing differentiation, not another me-too. Screen your SMID list for genuine best-in-class dosing or efficacy, then for cliff-fit at a specific buyer.
• Biosimilar makers: AbbVie's Humira at $688M/qtr (-40%) is the live case study in how fast biologic erosion runs once it starts, the same curve Stelara and, eventually, Keytruda will trace.
• SMID sentiment / XBI: one strong session and an IBB breakout, but a credible pundit is calling it rotation noise, not a regime change. Don't confuse a green day with a new tape.
• Bankers / CROs: 41 M&A deals worth $54.9B in Q1, 12 IPOs YTD, premiums rising, this is a banker's market. The FDA's reversal wave lowers clinical risk and should keep the deal and financing pipeline full.

What changed vs last week

This is the inaugural issue, so there's no prior week to diff against. Going forward this section will track rumor-to-deal conversions and deals that close or break. For the record this week: AbbVie/Apogee was rumored over the weekend and confirmed Monday, our first "rumor became a deal" data point, and on the quiet side, Merck, J&J, Vertex, Gilead and AstraZeneca generated no substantive podcast discussion at all. For names this cliff-exposed, silence in a record M&A week is worth noting, not ignoring.